SpectraScience Announces Presentation of WavSTAT4 Clinical Results for the Diagnosis of Small Colorectal Cancer Polyps at UEG...
October 04 2016 - 8:15AM
Marketwired
SpectraScience Announces Presentation of WavSTAT4 Clinical
Results for the Diagnosis of Small Colorectal Cancer Polyps at
UEGW
SAN DIEGO, CA-(Marketwired - Oct 4, 2016) - SpectraScience, Inc.
(OTCQB: SCIE), a medical device company utilizing light
technologies to detect and diagnose cancers, announced today that
Dr. Noor Mohammed of Leeds University, Leeds England, will present
clinical findings of the WavSTAT4 Optical Biopsy System at United
European Gastroenterology Week (UEGW) on October 19th. The WavSTAT4
Optical Biopsy System was once again found to exceed the clinical
guidelines adopted by EU and US medical societies for the diagnosis
of small and diminutive colorectal polyps during screening
colonoscopies.
"This study once again underscores the clinical accuracy of the
WavSTAT4 for diagnosing small polyps when used in colorectal cancer
screening. Optical characterization of these polyps in real time is
highly desired in order to permit the adoption of medical
strategies that would avoid the cost of traditional pathology and
prevent unnecessary polypectomies. Unlike image-based technologies
that are consistently shown not to work adequately unless in the
hands of experts and require complex human interpretations of the
data, our system works equally well with clinicians of virtually
all experience levels," said Michael Oliver, President and Chief
Executive Officer of SpectraScience, Inc. "Our system is fast, easy
to use and requires very little training for the clinician. It does
not require the clinician to change the colonoscopy procedure. The
WavSTAT Optical Biopsy System gives to all clinicians a diagnostic
capability equal to that of experts."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets spectrophotometry
systems capable of determining whether tissue is normal,
pre-cancerous or cancerous without physically removing tissue from
the body. Protected by more than 30 patents in 28 countries,
covering fundamental elements of the technology, the WavSTAT
Optical Biopsy System uses light to optically scan tissue and
provide the physician with an immediate analysis. With FDA approval
for sale in the U.S. and the CE Mark for the European Union, the
WavSTAT System is the first commercially available product that
incorporates this innovative patent protected technology for
clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that
involve risks and uncertainties that may cause SpectraScience's
actual results to differ materially from results discussed in
forward-looking statements. Readers are urged to carefully review
and consider the various disclosures made by SpectraScience in this
news release, its most recent Form 10-K and in SpectraScience's
other reports filed with the Securities and Exchange Commission
("SEC") that attempt to advise interested parties of the risks and
factors that may affect SpectraScience's business. These
forward-looking statements are qualified in their entirety by the
cautions and risk factors filed by SpectraScience in its annual
report on Form 10-K and other documents.
Contact Information
Contacts: Media and Investors: SpectraScience, Inc. Lowell
Giffhorn CFO Phone: (858) 847-0200 x2019 Email:
lgiffhorn@spectrascience.com
SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
From Oct 2024 to Nov 2024
SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
From Nov 2023 to Nov 2024
